TELA Bio (NASDAQ:TELA – Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Thursday, March 21st. Analysts expect TELA Bio to post earnings of ($0.44) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.
TELA Bio Price Performance
TELA opened at $5.55 on Thursday. The firm has a market cap of $135.91 million, a price-to-earnings ratio of -2.69 and a beta of 0.97. TELA Bio has a fifty-two week low of $4.23 and a fifty-two week high of $11.65. The company’s 50-day moving average price is $6.86 and its 200 day moving average price is $6.70. The company has a quick ratio of 4.43, a current ratio of 5.36 and a debt-to-equity ratio of 1.32.
Analysts Set New Price Targets
Separately, Lake Street Capital reiterated a “buy” rating and set a $14.00 price objective on shares of TELA Bio in a research note on Wednesday, December 27th.
Institutional Investors Weigh In On TELA Bio
Large investors have recently made changes to their positions in the company. Barclays PLC acquired a new stake in shares of TELA Bio in the second quarter valued at approximately $33,000. California State Teachers Retirement System acquired a new stake in shares of TELA Bio in the second quarter valued at approximately $53,000. Morgan Stanley increased its stake in shares of TELA Bio by 38,708.3% in the fourth quarter. Morgan Stanley now owns 4,657 shares of the company’s stock valued at $54,000 after purchasing an additional 4,645 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of TELA Bio by 8,294.9% in the second quarter. Wells Fargo & Company MN now owns 6,632 shares of the company’s stock valued at $67,000 after acquiring an additional 6,553 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of TELA Bio in the second quarter valued at approximately $83,000. Institutional investors and hedge funds own 91.06% of the company’s stock.
TELA Bio Company Profile
TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
See Also
- Five stocks we like better than TELA Bio
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- How to Find Cloud Software Company Stocks to Trade and Invest
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Williams-Sonoma Surged 20% and Could Double in Price
- How Technical Indicators Can Help You Find Oversold StocksĀ
- This Freight Stock Just Got an Upgrade and Institutional Buyers
Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.